leisure time -WSS

leisure time

author：explore 2025-09-07 17:23:12 - browse：312

Surgeons look over an x-ray monitor showing an implanted pacemaker — coverage from STAT — Adobe

In her final presentation for health policy class at the University of Chicago, first-year medical student Robin Ji informed her classmates that the Food and Drug Administration does not require randomized controlled trials of most medical devices. Her peers’ immediate reaction was disbelief.

“One classmate kept asking me, are you sure?” Ji said. “I think he asked me twice. Then he went on his phone to check to see if it was actually true.”

Ji was sure. She had spent two years before going to medical school working as a policy analyst for Rita Redberg and Sanket Dhruva, medical safety experts at the University of California, San Francisco. In a recent national survey published by the UCSF team in Health Affairs, Ji learned that it’s not just her classmates who may have misconceptions about the FDA — only 17% of physicians surveyed felt they understood the FDA’s device approval process. Around 41% felt they understood the drug side.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

WSS

The SUPPORT Act is critical to fighting the opioid crisis

FDA panel signals lack of confidence in Amgen cancer drug data

HHS names first

Biotech reporter’s notebook: A sunnier mood at JPM 2024

How I ended up pumping milk in a bathroom stall at JPM 2024

When women are denied an abortion, their children fare worse than peers

focus

leisure time

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

GSK to buy asthma

In Memoriam: Notable people who died in 2023

Caregivers of transplant patients call for more support, training

Sports medicine is finally prioritizing gender equality

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

23andMe had bad news about my health. I wish a person had delivered it

Generative AI mines health records to identify patients’ social needs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Was Amgen transparent enough on FDA's concern on cancer drug?

knowledge

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

FDA panel signals lack of confidence in Amgen cancer drug data

The future of health care in the House

Bristol 'take

The SUPPORT Act is critical to fighting the opioid crisis

The future of health care in the House

Wikipedia

Wikipedia

hotspot

hotspot